Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | KMT2A - MLLT10 |
Gene Variant Detail | |
Relevant Treatment Approaches | DOT1L Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
KMT2A - MLLT10 | leukemia | sensitive | DOT1L Inhibitor | EPZ004777 | Preclinical | Actionable | In a preclinical study, transformed cells expressing the fusion, KMT2A-MLLT10, demonstrated sensitivity to EPZ004777 in culture and in mouse models, resulting in cell cycle arrest, increased apoptotic activity, and inhibition of cell proliferation (PMID: 23138183). | 23138183 |
KMT2A - MLLT10 | acute myeloid leukemia | sensitive | DOT1L Inhibitor | I-BET151 + SGC0946 | Preclinical - Patient cell culture | Actionable | In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A-MLLT10 in culture (PMID: 27294782). | 27294782 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|